Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07529951) titled 'Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers' on April 8.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Eilean Therapeutics

Condition: Polycythemia Vera (PV) Myelofibrosis (MF)

Intervention: Drug: ZE74-0282

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: May 15, 2026

Target Sample Size: 60

To know more, visit https://clinicaltrials.gov/study/NCT07529951

Disclaimer: Curated by HT Syndication....